What we want to do

The aim of WAKE-UP is to provide a new safe and effective treatment option for acute stroke patients waking up with stroke symptoms. Every year about 2 million patients suffer a stroke in the EU and up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the only approved specific treatment available for acute stroke.

The core of WAKE-UP is an investigator-initiated, randomized, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. In this trial we will use modern multiparametric MRI techniques applying a new diagnostic algorithm to identify patients likely to benefit from treatment. In approximately 40 centres in six European countries we will enrol 800 patients of which 400 will receive intravenous tissue plasminogen activator (Alteplase), and 400 will receive placebo.

The trial will be accompanied by scientific work focussed on automated stroke MRI analysis as well as by activities increasing the awareness for acute stroke in the public.